Next Article in Journal
UV-Vis Spectrophotometry and UPLC–PDA Combined with Multivariate Calibration for Kappaphycus alvarezii (Doty) Doty ex Silva Standardization Based on Phenolic Compounds
Next Article in Special Issue
Phytochemistry and Evidence-Based Traditional Uses of the Genus Achillea L.: An Update (2011–2021)
Previous Article in Journal
Antiaging Properties of the Ethanol Fractions of Clove (Syzygium aromaticum L.) Bud and Leaf at the Cellular Levels: Study in Yeast Schizosaccharomyces pombe
Previous Article in Special Issue
Computer-Aided Design of Peptidomimetic Inhibitors of Falcipain-3: QSAR and Pharmacophore Models

New Frontiers on Adjuvants Drug Strategies and Treatments in Periodontitis

Department of General Surgery and Surgical-Medical Specialties, School of Dentistry, University of Catania, Via S. Sofia 78, 95123 Catania, Italy
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Dental School, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
Department of Orthodontics, School of Dentistry, University of Genova, Largo Rossana Benzi 10, 16132 Genova, Italy
Author to whom correspondence should be addressed.
Academic Editor: Helen D. Skaltsa
Sci. Pharm. 2021, 89(4), 46;
Received: 12 August 2021 / Revised: 10 October 2021 / Accepted: 19 October 2021 / Published: 22 October 2021
(This article belongs to the Special Issue Feature Papers in Scientia Pharmaceutica)
Causes of the progression of periodontitis such as an imbalance between the immune response by the host by the release of inflammatory mediators in the response of the oral pathogenic dysbiotic biofilm have been identified. New insights on specific cell signaling pathways that appear during periodontitis have attracted the attention of researchers in the study of new personalised approaches for the treatment of periodontitis. The gold standard of non-surgical therapy of periodontitis involves the removal of supra and subgingival biofilm through professional scaling and root planing (SRP) and oral hygiene instructions. In order to improve periodontal clinical outcomes and overcome the limitations of traditional SRP, additional adjuvants have been developed in recent decades, including local or systemic antibiotics, antiseptics, probiotics, anti-inflammatory and anti-resorptive drugs and host modulation therapies. This review is aimed to update the current and recent evolution of therapies of management of periodontitis based on the adjunctive and target therapies. Moreover, we discuss the advances in host modulation of periodontitis and the impact of targeting epigenetic mechanisms approaches for a personalised therapeutic success in the management of periodontitis. In conclusion, the future goal in periodontology will be to combine and personalise the periodontal treatments to the colonising microbial profile and to the specific response of the individual patient. View Full-Text
Keywords: periodontitis; adjuvants; drugs; antimicrobials; chemotherapeutic agents; dysbiosis; bacteria periodontitis; adjuvants; drugs; antimicrobials; chemotherapeutic agents; dysbiosis; bacteria
Show Figures

Figure 1

MDPI and ACS Style

Isola, G.; Polizzi, A.; Santonocito, S.; Dalessandri, D.; Migliorati, M.; Indelicato, F. New Frontiers on Adjuvants Drug Strategies and Treatments in Periodontitis. Sci. Pharm. 2021, 89, 46.

AMA Style

Isola G, Polizzi A, Santonocito S, Dalessandri D, Migliorati M, Indelicato F. New Frontiers on Adjuvants Drug Strategies and Treatments in Periodontitis. Scientia Pharmaceutica. 2021; 89(4):46.

Chicago/Turabian Style

Isola, Gaetano, Alessandro Polizzi, Simona Santonocito, Domenico Dalessandri, Marco Migliorati, and Francesco Indelicato. 2021. "New Frontiers on Adjuvants Drug Strategies and Treatments in Periodontitis" Scientia Pharmaceutica 89, no. 4: 46.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop